Adamant Biomedical Investments’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Adamant Biomedical Investments’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	$6K	Buy	+1,875	New	+$7.55K	﹤0.01%	99

Other funds holding AST

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

PCA

Private Capital Advisors Darien, Connecticut $1.14B AUM 48.66% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 19.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AIM

Allen Investment Management New York $8.43B AUM 20.31% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Adamant Biomedical Investments's AST Position: Q4 2014 in Review

Adamant Biomedical Investments opened a new position in Asterias Biotherapeutics Inc. Series A (AST) in Q4 2014: 1,875 shares worth $6K. The stake represents ﹤0.01% of the portfolio and ranks #99 among its holdings.

42 funds tracked by Wall St. Rank hold AST as of Q4 2014.

Adamant Biomedical Investments held 1,875 shares of Asterias Biotherapeutics Inc. Series A worth $6K as of Q4 2014.
Asterias Biotherapeutics Inc. Series A was a new Adamant Biomedical Investments position in Q4 2014.
Asterias Biotherapeutics Inc. Series A made up ﹤0.01% of Adamant Biomedical Investments's portfolio in Q4 2014, its #99 holding.
42 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.